Abstract
Enlightened by the modification route from Camptothecin (CPT) to Topotecan and based on classical drug design theory, a series of Mannich derivatives of lamellarin D were designed and synthesized in 26-27 steps starting from vanillin and isovanilin. All synthesized compounds were then biologically evaluated for their in vitro anti-cancer activities and Topo I inhibitory activities. The results showed that most target compounds exhibited Topo I inhibitory activities in equivalent level with that of lamellarin D. Compound SL-9 exhibited better Topo I inhibitory activity than that of lamellarin D. Compounds SL-2, SL-3, SL-4, SL-5 and SL-11 exhibited better anti-proliferative activity against HT-29 cells than that of lamellarin D.
Keywords:
Anti-cancer; Derivative; Lamellarin D; Mannich; Structure–activity relationships; Topo I.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Alkylation
-
Aquatic Organisms / chemistry*
-
Biological Products / chemical synthesis*
-
Biological Products / chemistry
-
Biological Products / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Chemistry Techniques, Synthetic
-
Coumarins / chemical synthesis*
-
Coumarins / chemistry
-
Coumarins / pharmacology*
-
DNA Topoisomerases, Type I / metabolism
-
Drug Design*
-
Heterocyclic Compounds, 4 or More Rings / chemical synthesis*
-
Heterocyclic Compounds, 4 or More Rings / chemistry
-
Heterocyclic Compounds, 4 or More Rings / pharmacology*
-
Humans
-
Isoquinolines / chemical synthesis*
-
Isoquinolines / chemistry
-
Isoquinolines / pharmacology*
-
Topoisomerase I Inhibitors / chemical synthesis
-
Topoisomerase I Inhibitors / chemistry
-
Topoisomerase I Inhibitors / pharmacology
Substances
-
Biological Products
-
Coumarins
-
Heterocyclic Compounds, 4 or More Rings
-
Isoquinolines
-
Topoisomerase I Inhibitors
-
lamellarin D
-
DNA Topoisomerases, Type I